Conference Materials

Access Legend-sponsored posters and presentations from recent scientific conferences.

Dominant-negative TGFBR2-armored DLL3-targeted CAR-T Cells Maintain TGF-β Resistance, With Early Signals of T-cell Exhaustion Modulation After Expansion in Patients With Small-cell Lung Carcinoma

Chuan Wang, Shuai Yang, Tao Zhao, Wang Zhang, Liping Sun, Zhong Yun, Mythili Koneru, Paul Schwarzenberger, Sahista Vahora, Christian Davis, Anqi Li, Jihong Dai, Luqing Ren, Wen Xie, Kevin Jhun, Zoe Zheng, and Dong Geng

Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2-targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma

David Zhen, Christos Fountzilas, Richard T. Maziarz, Emerson Y. Chen, Michael K. Gibson, Benjamin Oshrine, Mythili Koneru, Sahista Vahora, Christian Davis, Da Xu, and Anthony F. Shields

Safety, tolerability, and preliminary efficacy results from an ongoing Phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC

Jacob Sands, Alberto Chiappori, Ben Creelan, Paul Schwarzenberger, Mythili Koneru, Sahista Vahora, Christian Davis, Da Xu, Chuan Wang, Reinhold Munker, Zhonglin Hao, Adam J. Schoenfeld